<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03798964</url>
  </required_header>
  <id_info>
    <org_study_id>HYMC-0119-18</org_study_id>
    <nct_id>NCT03798964</nct_id>
  </id_info>
  <brief_title>The Expression Heparanase in Term and Preterm Placentas</brief_title>
  <official_title>The Expression Heparanase in Term and Preterm Placentas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hillel Yaffe Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hillel Yaffe Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heparanase is an endo-Î²-glucuronidase that cleaves heparin-sulfate (HS) side chains of
      heparan sulfate proteoglycans, an integral constituent of the extra cellular matrix (ECM).

      This study aims to investigate the association between heparanase expression in the human
      placenta and preterm birth (PTB) .

      The investigators hypothesize that an abnormal placentation causes relative placental
      ischemia that induces higher rates of heparanase expression.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2019</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Heparanase expression</measure>
    <time_frame>Six months</time_frame>
    <description>Heparanase expression in the human placenta following delivery will be evaluated by western blot analysis in the three groups and will be compared to determine differences in the levels.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Preterm Birth</condition>
  <arm_group>
    <arm_group_label>Elective term cesarean</arm_group_label>
    <description>Low-risk women undergoing elective term cesarean section</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Term vaginal delivery</arm_group_label>
    <description>Low-risk women undergoing term vaginal delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preterm vaginal delivery</arm_group_label>
    <description>Women undergoing preterm vaginal delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placental analysis</intervention_name>
    <description>Analysis of placenta to determine expression of heparanase</description>
    <arm_group_label>Elective term cesarean</arm_group_label>
    <arm_group_label>Preterm vaginal delivery</arm_group_label>
    <arm_group_label>Term vaginal delivery</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women attending our obstetrical unit
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Singleton pregnancy

        Exclusion Criteria:

          -  High-risk patients

          -  Multiple pregnancy

          -  Significant maternal illness

          -  Significant fetal anomaly
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rinat Gabbay-Benziv, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hillel Yaffe Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amir Naeh, MD</last_name>
    <phone>972-52-8656506</phone>
    <email>amir_naeh@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hille Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Amir Naeh, MD</last_name>
      <email>amir_naeh@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 2, 2019</study_first_submitted>
  <study_first_submitted_qc>January 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2019</study_first_posted>
  <last_update_submitted>January 9, 2019</last_update_submitted>
  <last_update_submitted_qc>January 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

